Abstract:Engineering immune cells to target cancer is a rapidly advancing technology. The first commercial products, chimeric-antigen receptor (CAR) T cells, are now approved for hematologic malignancies. However, solid tumors pose a greater challenge for cellular therapy, in part because suitable cancer-specific antigens are more difficult to identify and surrounding healthy tissues are harder to avoid. In addition, impaired trafficking of immune cells to solid tumors, the harsh immune-inhibitory microenvironment, and variable antigen density and presentation help tumors evade immune cells targeting cancer-specific antigens. To overcome these obstacles, T cells are being engineered to express defined T-cell receptors (TCR). Given that TCRs target intracellular peptides expressed on tumor MHC molecules, this provides an expanded pool of potential targetable tumor-specific antigens relative to the cell-surface antigens that are targeted by CAR T cells. The affinity of TCR T cells can be tuned to allow for better tumor recognition, even with varying levels of antigen presentation on the tumor and surrounding healthy tissue. Further enhancements to TCR T cells include improved platforms that enable more robust cell expansion and persistence; coadministration of small molecules that enhance tumor recognition and immune activation; and coexpression of cytokine-producing moieties, activating coreceptors, or mediators that relieve checkpoint blockade. Early-phase clinical trials pose logistical challenges involving production, large-scale manufacturing, and more. The challenges and obstacles to successful TCR T-cell therapy, and ways to overcome these and improve anticancer activity and efficacy, are discussed herein.

Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges

Genetically engineered T cells for cancer immunotherapy

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

Emerging Strategies in TCR-Engineered T Cells

TCR-T Immunotherapy: The Challenges and Solutions

TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu

The Screening, Identification, Design and Clinical Application of Tumor-Specific Neoantigens for TCR-T Cells

TCR engineered T cells for solid tumor immunotherapy

Progress in T cell receptor-gene engineered T cell immunotherapy for solid tumors

Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons

Progress in Neoantigen Targeted Cancer Immunotherapies

T-cell receptor-engineered T cells for cancer treatment: current status and future directions

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Targeting cancers through TCR-peptide/MHC interactions

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects

Neoantigens: promising targets for cancer therapy